Revolutionizing cancer treatment as new medical test Novlena enables early detection

In a groundbreaking breakthrough, scientists from biotech company Novelna in the United States have presented a DNA test capable of diagnosing 18 different types of cancer at an early stage.

The study, published in the journal BMJ Oncology, suggested that different tests may be needed for men and women indicating that cancer protein signals are sex-specific, as reported by the Daily Mail.

The research was carried out by collecting blood plasma samples from 44 healthy donors and 440 from people with different types of cancer.

They identified different proteins that showed signs of cancer and where they came from in the body.

However, further trials with a larger sample size need to be conducted for further studies.

By looking at the proteins in the blood plasma, the researchers proved successful in differentiating between different cancer cells from each other as well as from normal ones with 99% accuracy.

The advantages gained from this discovery could reshape screening guidelines by incorporating plasma testing as a standard component of routine screenings.

Director of the Center for Global Oncology at the Institute of Cancer Research, Dr Anguraj Sadanandam, said: “This research could pave the way for a prosperous and effective way of detecting cancers earlier when they are easier to treat.”

Dr Mangesh Thorat, of the Cancer Prevention Center at the Wolfson Institute for Preventive Medicine, said: “If the assay’s performance in future, well-designed follow-up studies is anywhere close to what this preliminary study suggests, then it could be a game-changer.” . .